Biotech: Page 17
-
The next era of Greater Boston’s biotech boom
How Boston became the biotech capital of the U.S., and is now preparing for the next era of life sciences growth.
By Karissa Waddick , Shaun Lucas , Julia Himmel • Nov. 22, 2022 -
Profile
How bacteria-enabled technology for wounds could also help cancer patients
Evelina Vågesjö, co-founder and CEO of the immunotherapy company Ilya Pharma, is working on a new modality to speed wound healing.
By Alexandra Pecci • Nov. 22, 2022 -
Trendline
Oncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
Q&A
In cancers with very low survival rates, Sellas aims higher
The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.
By Kelly Bilodeau • Nov. 21, 2022 -
Why the biopharma ‘IPO playbook’ changed in 2022
Biopharma IPOs have puttered in 2022, particularly compared to the record-breaking previous year, but they might be set to rebound.
By Michael Gibney • Nov. 21, 2022 -
Sponsored by ClinicalMind
Can a formal needs assessment simplify Speaker Bureau compliance?
In the biopharmaceutical industry, phases of innovation and change are often driven by regulatory action.
Nov. 21, 2022 -
Is AI just hype or a real revolution in pharma? It’s complicated
Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.
By Michael Gibney • Nov. 17, 2022 -
To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’
A new CRISPR-based tool could help scientists understand and better treat cancer by revealing the complex genetic mutations that occur.
By Michael Gibney • Nov. 16, 2022 -
#HLTH: ‘Unicorns are real’ — and here’s how they can navigate a challenging biotech market
Venture capitalists tackle ways companies can stay afloat while the market’s turbulent waters rise.
By Meagan Parrish • Nov. 15, 2022 -
Profile
A ‘bold vision’ to prevent diabetes
Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts.
By Alexandra Pecci • Nov. 15, 2022 -
4 ways to bring COVID’s ‘warp speed’ to the next era of drug development
An IQVIA Institute for Human Data Science report outlines how companies can improve communication, recruitment, data and investing strategies to accelerate clinical trial timelines.
By Kelly Bilodeau • Nov. 14, 2022 -
Opinion
Why the IRA will drive up the country’s drug bill — not lower it
On the surface, the Inflation Reduction Act is designed to lower drug prices, but its impact on innovation incentives could produce a landscape of new medicines that are costlier for patients.
By John LaMattina • Nov. 14, 2022 -
Q&A
Novo Nordisk’s quantum bet on ‘world changing’ computing
Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.
By Taren Grom • Nov. 10, 2022 -
3 ways pharma can weather a recession
If “winter is coming” in the form of a recession, pharmas can take advantage of an inherent resiliency by crushing these three fundamentals.
By Michael Gibney • Nov. 10, 2022 -
Profile
This plant-based gel stops bleeding in seconds — and might have potential in drug delivery
29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresolin and just inked a research partnership with Walter Reed.
By Karissa Waddick • Nov. 9, 2022 -
Podcast
Woman of the Week: 82VS’s Trier Bryant
Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Not every leader makes it their mission to go where the fire ...
By Taren Grom • Nov. 9, 2022 -
Profile
Chasing that ‘Time magazine cover potential’
Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.
By Alexandra Pecci • Nov. 8, 2022 -
While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help
Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.
By Michael Gibney • Nov. 8, 2022 -
After numerous setbacks, here’s where the Huntington’s pipeline stands
A look at emerging treatments and where there’s hope for patients.
By Kelly Bilodeau • Nov. 7, 2022 -
Sponsored by CorEvitas
Real world data: Understanding the scope of EHR and claims data
Using RWE alongside clinical trial data has the potential to streamline time-to-insight while generating a fuller and more patient-centric view of a given therapy’s efficacy.
Nov. 7, 2022 -
Acumen cruises into the fast lane with novel Alzheimer’s treatment
The company’s distinct amyloid-beta target, which just won a fast track designation, could give it an edge over the competition.
By Meagan Parrish • Nov. 3, 2022 -
Opinion
Pharma execs on creating a better workplace culture
Top women execs speak to the leadership skills they are embracing as the industry adjusts to a new normal.
By Taren Grom • Oct. 28, 2022 -
Riches, rags, riches: Is Biogen the Cinderella of biotechs?
Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.
By Michael Gibney • Oct. 27, 2022 -
Q&A // Biotech Spotlight
The first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology
Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.
By Karissa Waddick • Oct. 27, 2022 -
Profile
A longtime believer in mRNA, Strand Therapeutics’ co-founder is now pushing the tech to the next level
The company’s co-founder and head of R&D on how it’s using synthetic mRNA to create “smarter” therapies that could provide cures for cancer and more.
By Alexandra Pecci • Oct. 25, 2022 -
Beyond cancer: Scientists push CAR-T cell therapies into new frontiers
Why a ‘very exciting’ trial of the therapy in lupus patients could swing the door open to new studies in autoimmune diseases.
By Kelly Bilodeau • Oct. 24, 2022